Newswise — Waltham — December 19, 2023 — For patients undergoing total knee arthroplasty (TKA), treatment with diosmin – a flavonoid supplement derived from citrus fruits –reduced swelling of the knee and leg and some measures of associated pain can be achieved, reports a clinical trial in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
"The use of diosmin after TKA reduced lower-extremity swelling and pain during motion and was not associated with an increased incidence of short-term complications involving the outcomes studied," according to the new research by Pengde Kang, PhD, MD, of Sichuan University, Chengdu, China, and colleagues.
Possible new approach to alleviate painful swelling after TKA
Swelling is a common problem in patients undergoing TKA, and one that contributes to pain and patient dissatisfaction. "Postoperative lower-extremity swelling is a major hindrance to the enhanced recovery of patients undergoing TKA," the researchers write. Various measures have been proposed to decrease swelling, including rest, cold packs, and compressive bandages, with mixed success. Currently, there are no effective medication choices to reduce swelling after TKA.
Diosmin – often in combination with a related flavonoid called hesperidin – has been used to reduce swelling of the limbs in patients with venous disorders. Although diosmin is not approved as a prescription medication in the United States or Europe, experience suggests that it is well tolerated with low toxicity. Based on these characteristics, the researchers designed a clinical trial to evaluate the effectiveness and safety of diosmin in patients undergoing TKA.
The exploratory study included 330 patients undergoing TKA at 13 university-affiliated hospitals. Patients were randomly assigned to either a treatment group, receiving a 14-day course of diosmin starting postoperative day 1; or to a control group, receiving no study treatment. Both groups received standard pain medications.
Swelling at specific locations was measured at 1, 2, 3, and 14 days postoperatively and compared between the diosmin and control groups. Pain scores, knee function, complication rates, and blood levels of certain inflammatory markers (C-reactive protein and interleukin-6) were also assessed.
Diosmin reduces swelling and pain scores with movement
The results showed reduced swelling at the knee, calf, and thigh up to 14 days after TKA in patients assigned to diosmin. The reduction in swelling was associated with lower pain scores on knee movement. In contrast, pain scores at rest were not significantly different for the diosmin versus control groups. Assessments of knee function recovery and levels of inflammatory biomarkers were similar as well.
Short-term complication rates were also similar between groups, supporting the safety of diosmin. Thsere was a trend toward decreased rates of postoperative nausea and vomiting with diosmin, although the difference was not significant.
The study provides preliminary evidence that diosmin is a safe and effective treatment to reduce swelling and pain with movement after TKA. However, questions remain as to how diosmin exerts these effects – particularly since the study finds no change in inflammatory biomarker levels between groups.
"This negative result may reflect the efficacy of the other anti-inflammatory drugs that were administered to both groups," Dr. Kang and colleagues write. They emphasize the need for further studies to assess the mechanism by which diosmin reduces swelling, and whether some alternative dosing regimen might be more effective.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health.
###
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software, and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, and YouTube.
RSS